REPROCELL News | Clinical Capabilities

Oct 20, 2025

REPROCELL and Histocell Achieve GMP Certification for Manufacturing Process of Clinical-Grade iPSC Master and Working Cell Banks Using StemRNA™ Clinical iPSCs

REPROCELL and Histocell achieve GMP certification for clinical-grade iPSC manufacturing, advancing regenerative medicine and cell therapy production under EU regulations.

Nov 13, 2024

PRESS RELEASE: New Study Highlights Role of Stromal Support in Bioengineered Human Intestinal Models

New study by Prof Stefan Przyborski at Durham University enhances drug testing models with stromal support in bioengineered human intestinal tissue.

Feb 08, 2024

PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.

Jan 31, 2024

Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu

REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant.

Jan 15, 2024

Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives

SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.

Dec 15, 2023

End of 2023 Newsletter

Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.

Oct 04, 2023

REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs

Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing.

Jun 28, 2023

Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer

REPROCELL has entered into a joint research agreement with Keio University regarding the transfer of technology to produce Tumor Infiltrating Lymphocytes (TIL).

May 25, 2023

[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia

May 23, 2023

REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products

REPROCELL will now offer CDMO services to manufacture ATMPs generated from mesenchymal stem cells (MSC) through a partnership with Histocell.

May 03, 2023

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

REPROCELL USA has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “HARMONIC”.

Oct 13, 2022

REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers

REPROCELL Inc. and JTB Corp. will begin marketing Personal iPS (REPROCELL's iPSC storage and production service) overseas through the JMHC.

Oct 05, 2022

REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs

Learn why REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program.

Oct 04, 2022

REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs

REPROCELL and Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. Find out more.

Aug 09, 2022

Bioserve India granted NABL accreditation in the field of Genomics Testing

Bioserve Biotechnologies India Pvt Ltd has received NABL accreditation for Medical Testing in the field of Genomics Testing Services.

May 16, 2022

Completion of Clinical Phase II Trials of Stemchymal in Japan

We will endeavor to obtain clinical approval as soon as possible so that we can provide the new treatment to patients suffering from this disease.

Sep 02, 2021

REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service

REPROCELL USA has launched a new service to manufacture GMP iPSC-Master Cell Banks (MCB), compliant with the regulatory standards and guidelines.

Aug 18, 2021